Olivier Benveniste

List of Publications by Year
in descending order

162 papers	9,534 citations	31976 53 h-index	45317 90 g-index
173 all docs	173 docs citations	173 times ranked	7547 citing authors

#	Article	IF	Citations
1	Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. Human Gene Therapy, 2010, 21, 704-712.	2.7	776
2	Long-term observational study of sporadic inclusion body myositis. Brain, 2011, 134, 3176-3184.	7.6	319
3	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology, 2018, 75, 1528.	9.0	301
4	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology, 2018, 91, e985-e994.	1.1	247
5	Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies. Medicine (United States), 2014, 93, 150-157.	1.0	235
6	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmunity Reviews, 2012, 12, 210-217.	5.8	233
7	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016, 139, 2131-2135.	7.6	202
8	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 2018, 77, 30-39.	0.9	183
9	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018, 141, 1609-1621.	7.6	169
10	Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis and Rheumatism, 2011, 63, 1961-1971.	6.7	168
11	A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8. Molecular Therapy, 2011, 19, 2084-2091.	8.2	163
12	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14â€“16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.6	148
13	Interleukinâ€21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis and Rheumatism, 2012, 64, 2001-2011.	6.7	147
14	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology, 2020, 95, e70-e78.	1.1	142
15	Immune Checkpoint Inhibitorâ€“Associated Myositis. Circulation, 2018, 138, 743-745.	1.6	139
16	Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy. Human Gene Therapy, 2004, 15, 1065-1076.	2.7	134
17	Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain, 2015, 138, 2485-2492.	7.6	134
18	Necrosis in anti-SRP ⁺ and anti-HMGCR ⁺ myopathies. Neurology, 2018, 90, e507-e517.	1.1	132

#	Article	IF	Citations
19	Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nature Reviews Rheumatology, 2020, 16, 689-701.	8.0	131
20	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
21	Mechanisms Involved in the Lowâ€Level Regeneration of CD4+Cells in HIVâ€1â€“Infected Patients Receiving Highly Active Antiretroviral Therapy Who Have Prolonged Undetectable Plasma Viral Loads. Journal of Infectious Diseases, 2005, 191, 1670-1679.	4.0	115
22	Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathologica, 2015, 129, 611-624.	7.7	112
23	Pathogenic role of antiâ€“signal recognition protein and antiâ€“3â€Hydroxyâ€3â€methylglutarylâ€<scp>C</scp>o<scp>A</scp> reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Annals of Neurology, 2017, 81, 538-548.	5.3	112
24	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. European Respiratory Journal, 2013, 42, 1271-1282.	6.7	108
25	Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients. Seminars in Arthritis and Rheumatism, 2011, 41, 48-60.	3.4	107
26	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
27	In vivopathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Annals of the Rheumatic Diseases, 2019, 78, 131-139.	0.9	97
28	Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology, 2016, 29, 662-673.	3.6	96
29	Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies. Annals of the New York Academy of Sciences, 2008, 1132, 84-92.	3.8	93
30	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
31	Nuclear actin aggregation is a hallmark of anti-synthetase syndromeâ€“induced dysimmune myopathy. Neurology, 2015, 84, 1346-1354.	1.1	90
32	Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients. Journal of Immunology, 2001, 167, 3521-3529.	0.8	87
33	Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscular Disorders, 2006, 16, 334-336.	0.6	84
34	Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. PLoS ONE, 2015, 10, e0133702.	2.5	84
35	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81
36	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	5.8	80

#	Article	IF	Citations
37	A phase I trial of adeno-associated virus serotype 1-Î³-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain, 2012, 135, 483-492.	7.6	78
38	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. American Journal of Pathology, 2016, 186, 691-700.	3.8	78
39	IFN-Î²-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathologica, 2017, 134, 655-666.	7.7	78
40	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Safety, 2019, 42, 813-825.	3.2	78
41	Role of Regulatory T Cells in a New Mouse Model of Experimental Autoimmune Myositis. American Journal of Pathology, 2009, 174, 989-998.	3.8	74
42	Acquired necrotizing myopathies. Current Opinion in Neurology, 2013, 26, 554-560.	3.6	68
43	Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathologica Communications, 2014, 2, 154.	5.2	68
44	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90.	6.5	67
45	Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e523.	6.0	66
46	Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain, 2006, 129, 986-995.	7.6	65
47	Th1 Response and Systemic Treg Deficiency in Inclusion Body Myositis. PLoS ONE, 2014, 9, e88788.	2.5	65
48	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight, 2020, 5, .	5.0	65
49	Sarcoidosis and interferon therapy: report of five cases and review of the literature. European Journal of Internal Medicine, 2003, 14, 237-243.	2.2	58
50	Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Research and Therapy, 2014, 16, R39.	3.5	57
51	MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. Journal of Neuroimmunology, 2005, 170, 41-48.	2.3	55
52	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. PLoS ONE, 2020, 15, e0240711.	2.5	54
53	Myositis or dystrophy? Traps and pitfalls. Presse Medicale, 2011, 40, e249-e255.	1.9	53
54	Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathologica Communications, 2016, 4, 45.	5.2	52

#	Article	IF	Citations
55	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
56	IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clinical Immunology, 2004, 111, 241-251.	3.2	49
57	Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use. Journal of Rheumatology, 2012, 39, 1835-1839.	2.0	48
58	Biomarkers in Inflammatory Myopathiesâ€"An Expanded Definition. Frontiers in Neurology, 2019, 10, 554.	2.4	48
59	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75.	2.6	44
60	Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmunity Reviews, 2019, 18, 223-230.	5.8	44
61	The role of interferons type I, II and III in myositis: A review. Brain Pathology, 2021, 31, e12955.	4.1	44
62	Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscular Disorders, 2012, 22, 980-986.	0.6	43
63	Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 11.	3.3	42
64	PD1 pathway in immune-mediated myopathies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e558.	6.0	42
65	Sequestosomeâ€1 (p62) expression reveals chaperoneâ€assisted selective autophagy in immuneâ€mediated necrotizing myopathies. Brain Pathology, 2020, 30, 261-271.	4.1	42
66	Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies. Journal of Immunology Research, 2014, 2014, 1-8.	2.2	41
67	Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials. Neuromuscular Disorders, 2014, 24, 604-610.	0.6	41
68	Immuneâ€Array Analysis in Sporadic Inclusion Body Myositis Reveals HLAâ€"DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	5.6	41
69	Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscular Disorders, 2017, 27, 251-258.	0.6	41
70	Paradoxical intracranial cryptococcoma in a human immunodeficiency virusâ€"infected man being treated with combination antiretroviral therapy. American Journal of Medicine, 2002, 113, 155-157.	1.5	40
71	Sporadic late-onset nemaline myopathy with MGUS. Neurology, 2014, 83, 2133-2139.	1.1	40
72	Cytokine mRNA Expression in Mononuclear Cells from Different Tissues during Acute SIVmac251 Infection of Macaques. AIDS Research and Human Retroviruses, 1996, 12, 1263-1272.	1.1	39

#	Article	IF	Citations
73	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrology Dialysis Transplantation, 2017, 33, 1579-1590.	0.7	37
74	Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. Journal of Rheumatology, 2019, 46, 623-627.	2.0	36
75	The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. Journal of Autoimmunity, 2016, 75, 118-129.	6.5	34
76	The IgG2 Isotype of Antiâ€“Transcription Intermediary Factor 1Î³ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis and Rheumatology, 2019, 71, 1360-1370.	5.6	33
77	Expression of myogenic regulatory factors and myo-endothelial remodeling in sporadic inclusion body myositis. Neuromuscular Disorders, 2013, 23, 75-83.	0.6	32
78	Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatology, The, 2021, 3, e40-e48.	3.9	32
79	Cytokine mRNA levels in unmanipulated (ex vivo) and in vitro stimulated monkey PBMCs using a semi-quantitative RT-PCR and high sensitivity fluorescence-based detection strategy. Cytokine, 1996, 8, 32-41.	3.2	31
80	Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. Journal of Neuromuscular Diseases, 2018, 5, 241-249.	2.6	31
81	Interleukin 1Î², Interleukin 6, Tumor Necrosis Factor Î±, and Interleukin 10 Responses in Peripheral Blood Mononuclear Cells of Cynomolgus Macaques during Acute Infection with SIVmac251. AIDS Research and Human Retroviruses, 1996, 12, 241-250.	1.1	30
82	Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. Current Opinion in Neurology, 2017, 30, 457-463.	3.6	30
83	Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments. Ultrasound in Medicine and Biology, 2018, 44, 1423-1432.	1.5	30
84	Successful Percutaneous Dihydrotestosterone Treatment of Gynecomastia Occurring during Highly Active Antiretroviral Therapy: Four Cases and a Review of the Literature. Clinical Infectious Diseases, 2001, 33, 891-893.	5.8	28
85	Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. Seminars in Arthritis and Rheumatism, 2020, 50, 1437-1440.	3.4	28
86	Beneficial Role of Rapamycin in Experimental Autoimmune Myositis. PLoS ONE, 2013, 8, e74450.	2.5	27
87	MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathology, 2021, 31, e12954.	4.1	27
88	Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. Journal of Immunology, 2016, 197, 1621-1630.	0.8	26
89	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmunity Reviews, 2021, 20, 102729.	5.8	26
90	Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry. PLoS ONE, 2018, 13, e0194593.	2.5	26

#	Article	IF	Citations
91	Two Episodes of Acute Renal Failure, Rhabdomyolysis, and Severe Hepatitis in an AIDS Patient Successively Treated with Ritonavir and Indinavir. Clinical Infectious Diseases, 1999, 28, 1180-1181.	5.8	23
92	Endocarditis Due to Neisseria bacilliformis in a Patient with a Bicuspid Aortic Valve. Journal of Clinical Microbiology, 2009, 47, 1973-1975.	3.9	22
93	CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis. Autoimmunity Reviews, 2019, 18, 325-333.	5.8	21
94	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18â€“20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.6	19
95	Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e451.	6.0	19
96	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet Journal of Rare Diseases, 2018, 13, 127.	2.7	19
97	Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). European Radiology, 2019, 29, 5139-5147.	4.5	19
98	Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. European Radiology, 2021, 31, 4264-4276.	4.5	19
99	Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144, 353-372.	7.7	19
100	Local Texture Anisotropy as an Estimate of Muscle Quality in Ultrasound Imaging. Ultrasound in Medicine and Biology, 2018, 44, 1133-1140.	1.5	18
101	Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. European Journal of Internal Medicine, 2020, 80, 78-85.	2.2	18
102	Rituximab and Cyclophosphamide in Antisynthetase Syndromeâ€“related Interstitial Lung Disease: An Observational Retrospective Study. Journal of Rheumatology, 2020, 47, 1678-1686.	2.0	18
103	Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. Journal of the American Academy of Dermatology, 2020, 83, 1759-1763.	1.2	18
104	Lack of Interleukin 10 Expression in Monocyte-Derived Macrophages in Response toin VitroInfection by HIV Type 1 Isolates. AIDS Research and Human Retroviruses, 1997, 13, 961-966.	1.1	17
105	HTLV-1-associated inflammatory myopathies: Low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. Journal of Clinical Virology, 2013, 57, 70-76.	3.1	17
106	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	1.9	17
107	The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmunity Reviews, 2021, 20, 102788.	5.8	17
108	Physical activity monitoring: A promising outcome measure in idiopathic inflammatory myopathies. Neurology, 2017, 89, 101-103.	1.1	16

#	Article	IF	Citations
109	Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Current Opinion in Rheumatology, 2018, 30, 655-663.	4.3	16
110	Autoantibody testing in idiopathic inflammatory myopathies. Practical Neurology, 2019, 19, 284-294.	1.1	16
111	Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy. Annals of Hematology, 2017, 96, 695-696.	1.8	15
112	Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. Joint Bone Spine, 2018, 85, 375-376.	1.6	14
113	Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. Autoimmunity Reviews, 2020, 19, 102465.	5.8	14
114	Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 38, 101869.	2.0	14
115	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 1140-1149.	3.4	14
116	Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. Journal of Neuroimmunology, 2019, 332, 212-215.	2.3	13
117	Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis. Brain Pathology, 2020, 30, 867-876.	4.1	13
118	Tumor necrosis factorâ€alpha in serum of macaques during SIV_{mac251} acute infection. Journal of Medical Primatology, 1995, 24, 94-100.	0.6	12
119	Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011. Presse Medicale, 2011, 40, e197-e198.	1.9	12
120	Expanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations. Neuropathology and Applied Neurobiology, 2015, 41, 849-852.	3.2	12
121	Inclusion body myositis: accumulation of evidence for its autoimmune origin. Brain, 2019, 142, 2549-2551.	7.6	12
122	Correspondence on â€˜Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric surveyâ€™. Annals of the Rheumatic Diseases, 2023, 82, e30-e30.	0.9	11
123	NanoString technology distinguishes antiâ€TIFâ€1Î³⁺ from antiâ€Miâ€2⁺ dermatomyositis patients. Brain Pathology, 2021, 31, e12957.	4.1	11
124	Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies. Current Rheumatology Reports, 2018, 20, 56.	4.7	10
125	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	2.5	10
126	Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PLoS ONE, 2020, 15, e0233460.	2.5	9

#	Article	IF	Citations
127	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie, 2021, 76, 285-295.	1.0	8
128	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells, 2021, 10, 2551.	4.1	8
129	Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. Journal of Neuromuscular Diseases, 2019, 6, 99-107.	2.6	7
130	Expanding the spectrum of HIV-associated myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1296-1298.	1.9	7
131	Routine monitoring of isometric knee extension strength in patients with muscle impairments using a new portable device: cross-validation against a standard isokinetic dynamometer. Physiological Measurement, 2020, 41, 015003.	2.1	7
132	Endoplasmic reticulumâ€stress and unfolded protein responseâ€activation in immuneâ€mediated necrotizing myopathy. Brain Pathology, 2022, 32, .	4.1	7
133	Nef and Gag Synthetic Peptide Priming of Antibody Responses to HIV Type 1 Antigens in Mice and Primates. AIDS Research and Human Retroviruses, 1994, 10, 1241-1250.	1.1	6
134	Distal inflammatory myopathy: Unusual presentation of polymyositis or new entity?. Neuromuscular Disorders, 2008, 18, 493-500.	0.6	6
135	Lean regional muscle volume estimates using explanatory bioelectrical models in healthy subjects and patients with muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 39-51.	7.3	6
136	Gene therapy, an ongoing revolution. Blood, 2012, 119, 2973-2974.	1.4	5
137	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on â€œUrgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndromeâ€•by Quartuccio et al. Joint Bone Spine. 2020;87:191â€“93. Joint Bone Spine, 2021, 88, 105074.	1.6	5
138	Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain, 2018, 141, e81-e81.	7.6	4
139	Quickly progressive amyotrophy of the thigh: An unusual cause of rapid chondrolysis of the knee. Joint Bone Spine, 2015, 82, 203-205.	1.6	3
140	Dermoskeletics to preserve mobility and function in inclusion body myositis. Neurology, 2018, 91, 760-760.	1.1	3
141	Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e60-e60.	7.6	3
142	Functional Consequences of Macrophage Infection by Human Immunodeficiency Virus: Bispecific Antibody Targeting of HIV-1-Infected Cells to FcÎ³RI Expressing Effector Cells. Stem Cells and Development, 1995, 4, 579-585.	1.0	2
143	Interferonâ€Î± Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et al. Arthritis and Rheumatology, 2014, 66, 2308-2309.	5.6	2
144	Response to: â€˜Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€™ by Cavagnaet al. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-212382.	0.9	2

#	Article	IF	Citations
145	Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease. Orphanet Journal of Rare Diseases, 2019, 14, 4.	2.7	2
146	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. Autoimmunity Reviews, 2021, 20, 102874.	5.8	2
147	Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain, 2019, 142, e9-e9.	7.6	1
148	Response to: Comment on â€œSystematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyâ€• Journal of the American Academy of Dermatology, 2020, 83, e461-e462.	1.2	1
149	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. Archives of Cardiovascular Diseases, 2022, 115, 96-96.	1.6	1
150	Four cross-linked HIV Gag peptides prime the immune response to HIV proteins in mice. Peptides, 1994, 15, 935-943.	2.4	0
151	Autoantibodies at the Center of (sub)Classificationâ€”Issues of Detectionâ€”Reply. JAMA Neurology, 2019, 76, 868.	9.0	0
152	Infliximab as effective treatment for aseptic neutrophilic myositis. Neurology, 2019, 93, 1009-1011.	1.1	0
153	Response to: â€˜On using machine learning algorithms to define clinically meaningful patient subgroupsâ€™ by Pinal-Fernandez and Mammen. Annals of the Rheumatic Diseases, 2020, 79, e130-e130.	0.9	0
154	La myosite Ã inclusions. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 91-103.	0.0	0
155	Title is missing!. , 2020, 15, e0233460.		0
156	Title is missing!. , 2020, 15, e0233460.		0
157	Title is missing!. , 2020, 15, e0233460.		0
158	Title is missing!. , 2020, 15, e0233460.		0
159	Title is missing!. , 2020, 15, e0240711.		0
160	Title is missing!. , 2020, 15, e0240711.		0
161	Title is missing!. , 2020, 15, e0240711.		0
162	Title is missing!. , 2020, 15, e0240711.		0